CDK
Les inhibiteurs des kinases dépendantes des cyclines (CDK) sont des composés qui bloquent l'activité des CDK, un groupe de kinases protéiques qui régulent le cycle cellulaire, la transcription et d'autres processus cellulaires. Les CDK sont activées par leur liaison aux cyclines, et leur activité est cruciale pour la progression des cellules à travers les différentes phases du cycle cellulaire. Inhiber les CDK peut arrêter la division cellulaire, entraînant un arrêt du cycle cellulaire et l'apoptose, en particulier dans les cellules cancéreuses où les CDK sont souvent dysrégulées. Les inhibiteurs de CDK sont largement utilisés dans la recherche sur le cancer et ont un potentiel thérapeutique dans le traitement de divers cancers. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de CDK de haute qualité pour soutenir vos recherches sur le contrôle du cycle cellulaire, le cancer et le développement thérapeutique.
500 produits trouvés pour "CDK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Cdc7-IN-1
CAS :<p>Cdc7-IN-1: selective ATP-competitive Cdc7 kinase inhibitor; IC50 0.6 nM at 1mM ATP; induces cancer cell death.</p>Formule :C21H16ClN3O4Couleur et forme :SolidMasse moléculaire :409.82CDK9-IN-14
CAS :<p>CDK9-IN-14: Potent CDK9 inhibitor, IC50=6.92 nM, effective on MV-4-11 cells and in vivo tumors, low toxicity, minimal side effects.</p>Formule :C21H23F2N3O4Couleur et forme :SolidMasse moléculaire :419.42CLK1/2-IN-3
CAS :<p>CLK1/2-IN-3 (Cpd-3) is a CLK1 and CLK2 inhibitor with antiproliferative activity that inhibits the activity of CLK and SRPK.</p>Formule :C21H21N5O2Degré de pureté :99.04%Couleur et forme :SolidMasse moléculaire :375.42THZ1-R
CAS :<p>THZ1-R is a non-covalent active analogue of THZ1, with the acrylamide group removed from THZ1, not covalently bind to the C312 cysteine residue of CDK7.</p>Formule :C31H30ClN7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :568.07CLK1-IN-1
CAS :<p>CLK1-IN-1 is a potent and selective inhibitor of the Cdc2-like kinase 1 (CLK1; IC50: 2 nM).</p>Formule :C24H16FN5OCouleur et forme :SolidMasse moléculaire :409.42CDK12-IN-E9
CAS :<p>CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and non-covalent CDK9 inhibitor while avoiding ABC transporter-mediated efflux.</p>Formule :C24H30N6O2Couleur et forme :SolidMasse moléculaire :434.53Cdc7-IN-17
CAS :<p>Cdc7-IN-17 is a potent inhibitor of CDC7 with an IC 50 of <10 μM that can be used in cancer research [1].</p>Formule :C13H15N5OSCouleur et forme :SolidMasse moléculaire :289.36AS2863619 free base
CAS :<p>AS2863619 free base enables the conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells.</p>Formule :C16H12N8OCouleur et forme :SolidMasse moléculaire :332.32Cdc7-IN-4
CAS :<p>Cdc7-IN-4 is a potent inhibitor of Cdc7 kinase.</p>Formule :C22H24F3N5O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :479.45K 00546
CAS :<p>K00546 inhibits CDK1/cyclin B (IC50: 0.6 nM), CDK2/cyclin A (IC50: 0.5 nM), CLK1 (IC50: 8.9 nM), and CLK3 (IC50: 29.2 nM).</p>Formule :C15H13F2N7O2S2Degré de pureté :99.12%Couleur et forme :SolidMasse moléculaire :425.44CDK8-IN-7
CAS :<p>CDK8-IN-7 is a potent CDK8 inhibitor with a Kd of 3.5 nM, showing promise for AML research.</p>Formule :C30H40N2Couleur et forme :SolidMasse moléculaire :428.65Cdc7-IN-15
CAS :<p>Cdc7-IN-15 (Example 108) is an inhibitor of cdc7 kinase that has potential to be used for cancer research [1].</p>Formule :C12H14N4OSCouleur et forme :SolidMasse moléculaire :262.33CP681301
CAS :<p>CP681301 is a potent CDK5 inhibitor with anti-tumor effects in Drosophila and reduces Glioma stem cells' growth and renewal.</p>Formule :C17H22N4OCouleur et forme :SolidMasse moléculaire :298.38MDK6204
CAS :<p>MDK6204 is a selective inhibitor of CLK1 and CLK2.</p>Formule :C20H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :360.41BSJ-01-175
CAS :<p>BSJ-01-175: Selective, potent covalent inhibitor of CDK12/13, targets cancer cells, inhibits phosphorylated RNA polymerase II, downregulates CDK12 genes.</p>Formule :C30H33ClN6O2Couleur et forme :SolidMasse moléculaire :545.08Indirubin-3'-monoxime-5-sulphonic acid
CAS :<p>Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of GSK-3β, CDK5, and CDK1 with IC50s of 80nM,5 nM, and 7 nM, respectively.</p>Formule :C16H11N3O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :357.34CDK7-IN-13
CAS :<p>CDK7-IN-13: A potent pyrimidine-based CDK7 inhibitor, potential for various cancers. See CN114249712A.</p>Formule :C20H23F3N6OSDegré de pureté :99.22%Couleur et forme :SolidMasse moléculaire :452.5P18IN003
CAS :<p>P18IN003 is a selective and effective p18(INK4C) inhibitor that inhibits the activity of p18 protein and can be used to study in vitro expansion of</p>Formule :C17H16N2O3Degré de pureté :98.77%Couleur et forme :SolidMasse moléculaire :296.32CDK7-IN-20
<p>CDK7-IN-20: potent, irreversible CDK7 inhibitor, IC50 of 4nM, 206x selectivity vs. other CDKs, potential for ADPKD study.</p>Formule :C30H26N6O3Couleur et forme :SolidMasse moléculaire :518.57FLT3/CDK4-IN-1
CAS :<p>FLT3/CDK4-IN-1: Oral FLT3 (7 nM IC50) & CDK4 (11 nM IC50) inhibitor with strong in vivo anti-cancer properties.</p>Formule :C25H28F2N8Couleur et forme :SolidMasse moléculaire :478.54BS-181
CAS :<p>BS-181 is a highly selective CDK7 inhibitor (IC50: 21 nM); >40-fold selective for CDK7 than CDK1/2/4/5/6/9.</p>Formule :C22H32N6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :380.53CDK4/6-IN-12
CAS :<p>CDK4/6-IN-12 inhibits CDK4/6 with IC50s of 592.3 nM & 3090 nM, useful in cancer research.</p>Formule :C12H10N6Couleur et forme :SolidMasse moléculaire :238.25CGP60474
CAS :<p>CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC.</p>Formule :C18H18ClN5ODegré de pureté :98.81%Couleur et forme :SolidMasse moléculaire :355.82CCT068127
CAS :<p>CCT068127 is a potent CDK2 and CDK9 inhibitor.</p>Formule :C19H27N7OCouleur et forme :SolidMasse moléculaire :369.46(S)-CR8
CAS :<p>(S)-CR8 is an effective second-generation cyclin-dependent kinase inhibitor.</p>Formule :C24H29N7OCouleur et forme :SolidMasse moléculaire :431.53CDK7-IN-8
CAS :<p>CDK7-IN-8 is a potent inhibitor of CDK7 (IC50: 54.29 nM) and exhibits inhibitory activity against several cancer cells and in vivo tumor models.</p>Formule :C25H38N8O3Couleur et forme :SolidMasse moléculaire :498.62EGFR/HER2/CDK9-IN-3
CAS :<p>EGFR/HER2/CDK9-IN-3 inhibits EGFR (191.08 nM IC50), HER2 (132.65 nM), CDK9 (113.98 nM); shows anti-tumor effects.</p>Formule :C24H21N3O4S2Couleur et forme :SolidMasse moléculaire :479.57Aloisine A
CAS :<p>Aloisine A, a CDK/GSK-3 inhibitor with IC50: Cdk1/B-150nM, Cdk2/A-120nM, Cdk2/E-400nM, Cdk5/25-200nM, Cdk5/35-160nM, GSK-3α-500nM, GSK-3β-650nM, JNK-3-10μM.</p>Formule :C16H17N3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :267.33TP1287
CAS :<p>TP-1287 is an oral phosphate prodrug of the CDK9 inhibitor, alvocidib.</p>Formule :C21H21ClNO8PCouleur et forme :SolidMasse moléculaire :481.82Indirubin-5-sulfonate
CAS :<p>Indirubin-5-sulfonate inhibits GSK-3β & CDKs with IC50: 55/35/150/300/65 nM for CDK1/B, 2/A&E, 4/D1, 5/p35.</p>Formule :C16H10N2O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :342.33Crozbaciclib fumarate
CAS :<p>Crozbaciclib fumarate is a CDK4/6 inhibitor with IC 50 s of 3 and 1 nM, respectively.</p>Formule :C32H34F2N6O4Couleur et forme :SolidMasse moléculaire :604.65CDK7-IN-12
CAS :<p>CDK7-IN-12 inhibits CDK7 to control transcription and cell cycle, halting tumor growth in vitro/vivo with cancer research potential.</p>Formule :C20H19F3N6Couleur et forme :SolidMasse moléculaire :400.4CDK1-IN-1
CAS :<p>CDK1-IN-7 inhibits CDK1 at 161.2 nM, triggers p53-dependent apoptosis, and selectively targets tumor growth.</p>Formule :C27H23N5O3Couleur et forme :SolidMasse moléculaire :465.5CDK4/6-IN-9
CAS :<p>CDK4/6-IN-9 selectively inhibits CDK4/6 (IC50: 905 nM); potential for MM research.</p>Formule :C22H23FN8Couleur et forme :SolidMasse moléculaire :418.47Cdc7-IN-13
CAS :<p>Cdc7-IN-13 (compound 84) is a highly potent CDC7 inhibitor, exhibiting an IC50 value of <1 nM. This compound holds promise for cancer research [1].</p>Formule :C18H20N4O2SCouleur et forme :SolidMasse moléculaire :356.44Ulecaciclib
CAS :<p>Ulecaciclib: oral, BBB-permeable CDK inhibitor; favorable pharmacokinetics; ki: 0.62 μM (CDK2/A), 3 nM (CDK6/D3), 0.2 nM (CDK4/D1), 0.63 μM (CDK7/H).</p>Formule :C25H33FN8SCouleur et forme :SolidMasse moléculaire :496.65FN-1501
CAS :<p>FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively).</p>Formule :C22H25N9ODegré de pureté :97.4%Couleur et forme :SolidMasse moléculaire :431.49JTK-101
CAS :<p>JTK-101 is a potent and selective Tat-dependent HIV-1 replication inhibitor.</p>Formule :C25H23N3O3Couleur et forme :SolidMasse moléculaire :413.47(E/Z)-BIO-acetoxime
CAS :<p>(E/Z)-BIO-acetoxime: potent GSK-3 α/β inhibitor; IC50: GSK-3α/β 10nM, CDK5/p25 2.4μM, CDK2/A 4.3μM, CDK1/B 63μM.</p>Formule :C18H12BrN3O3Couleur et forme :SolidMasse moléculaire :398.21(S)-LY3177833 hydrate
CAS :<p>(S)-LY3177833 ((S)-Example 2) hydrate, an orally active CDC7 kinase inhibitor, exhibits extensive in vitro anticancer efficacy.</p>Formule :C16H14FN5O2Couleur et forme :SolidMasse moléculaire :327.31RP-106
CAS :<p>RP-106 is an ATP-competitive inhibitor of CDK5/p25, CDK1/cyclin B, and GSK-3.</p>Formule :C17H19N3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :281.35PKC-9
CAS :<p>PKC-9 is a PKC-zeta inhibitor 9.</p>Formule :C25H25N7Couleur et forme :SolidMasse moléculaire :423.51CDK4/6-IN-7
CAS :<p>CDK4/6-IN-7 is an oral, potent CDK4/6 inhibitor with IC50s of 1.58/4.09 nM, crucial for breast cancer studies.</p>Formule :C18H18ClN5O3Couleur et forme :SolidMasse moléculaire :387.82Cdc7-IN-3
CAS :<p>Cdc7-IN-3 is a potent inhibitor of Cdc7 kinase.</p>Formule :C20H22N4O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :398.41CDK7-IN-2
CAS :<p>CDK7-IN-2 inhibits CDK7, essential for RNA polymerase II activation and cell cycle control, with cancer research potential.</p>Formule :C26H39N7O3Couleur et forme :SolidMasse moléculaire :497.63EGFR/HER2/CDK9-IN-1
CAS :<p>EGFR/HER2/CDK9-IN-1 is a potent inhibitor (IC50: EGFR 90.17 nM, HER2 131.39 nM, CDK9 67.04 nM) with notable anti-tumor activity.</p>Formule :C23H21N3O3S2Couleur et forme :SolidMasse moléculaire :451.56CDK5 inhibitor 20-223
CAS :<p>CDK5 inhibitor 20-223 is a potent CDK2/CDK5 inhibitor,anti-Colorectal Cancer (CRC), inhibiting cell migration and inducing cell cycle arrest.</p>Formule :C19H19N3OCouleur et forme :SolidMasse moléculaire :305.37FN-1501-propionic acid
CAS :<p>FN-1501-propionic acid, a CDK2/9 ligand, in conjunction with a CRBN ligand, has been utilized in the design of a PROTAC CDK2/9 degrader.</p>Formule :C25H27N9O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :517.54EGFR/HER2/CDK9-IN-2
CAS :<p>EGFR/HER2/CDK9-IN-2 inhibits EGFR, HER2, CDK9 with IC50s: 145.35, 129.07, 117.13 nM; strong antitumor effects.</p>Formule :C23H20N4O5S2Couleur et forme :SolidMasse moléculaire :496.56CDK8-IN-10
CAS :<p>CDK8-IN-10 is a selective and potent inhibitor of cell cycle protein-dependent kinase (CDK8) (IC50: 8.25 nM) that can be used to study cancer.</p>Formule :C25H15ClF3N5O3Couleur et forme :SolidMasse moléculaire :525.87CDK4/6-IN-8
CAS :<p>CDK4/6-IN-8 (Compound 7p) is a selective inhibitor of CDK4 (IC50=5.01 nM) and CDK6 (IC50=3.97 nM).</p>Formule :C18H18N6O5Couleur et forme :SolidMasse moléculaire :398.37AS-0141
CAS :<p>AS-0141 (Cdc7-IN-6) 是一种有效的 Cdc7 激酶抑制剂 (IC50=4 nM)，具有抗肿瘤活性。Cdc7 是一种丝氨酸苏氨酸蛋白激酶酶，在细胞周期中对 DNA 复制的启动至关重要。</p>Formule :C21H22F3N5O4Degré de pureté :99.97%Couleur et forme :SolidMasse moléculaire :465.43Ryuvidine
CAS :<p>Ryuvidine is a dual inhibitor of KDM5A and SETD8, an inducer of the DNA damage response, and can be used to study breast cancer and erythroderma.</p>Formule :C15H12N2O2SDegré de pureté :98.6%Couleur et forme :SolidMasse moléculaire :284.33(S)-Enitociclib
CAS :<p>(S)-Enitociclib (VIP152) is a selective CDK9 inhibitor that inhibits the transcription of anti-apoptotic and pro-survival proteins.</p>Formule :C19H18F2N4O2SDegré de pureté :98.98%Couleur et forme :SolidMasse moléculaire :404.43CLK-IN-T3
CAS :<p>CLK-IN-T3 is an inhibitor of CLK1, CLK2, and CLK3 with IC50s of 0.67, 15, and 110 nM. CLK-IN-T3 exhibits anti-cancer activity.</p>Formule :C28H30N6O2Degré de pureté :99.61%Couleur et forme :SolidMasse moléculaire :482.58(S)-PF-06873600
CAS :<p>(S)-PF-06873600 is the S enantiomer of PF-06873600 which is an inhibitor of CDK.</p>Formule :C20H27F2N5O4SDegré de pureté :98.59%Couleur et forme :SolidMasse moléculaire :471.52CDK9-IN-10
CAS :<p>CDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.</p>Formule :C22H16O5Degré de pureté :99.8%Couleur et forme :SolidMasse moléculaire :360.36PS423
CAS :<p>PS423 is a substrate-selective protein kinase PDK1 inhibitor that acts by binding to the PIF-pocket allosteric docking site.</p>Formule :C25H23F3O9Degré de pureté :98.81% - 99.26%Couleur et forme :SolidMasse moléculaire :524.44HTH-01-091
CAS :<p>HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor (IC50: 10.5 nM).HTH-01-091 inhibits PIM1/2/3, RIPK2, DYRK3,</p>Formule :C26H28Cl2N4O2Degré de pureté :98.4%Couleur et forme :SolidMasse moléculaire :499.43hSMG-1 inhibitor 11e
CAS :<p>hSMG-1 inhibitor 11e is an effective and selective inhibitor of hSMG-1 (IC50 <0.05 nM) and can be used in studies about cancer treatment.</p>Formule :C26H27N7O3SDegré de pureté :99.89%Couleur et forme :SolidMasse moléculaire :517.6CDK-IN-2
CAS :<p>CDK-IN-2 (CDK inhibitor II) is a potent and specific CDK9 inhibitor (IC50: <8 nM).</p>Formule :C18H19ClFN3O2Degré de pureté :99.67%Couleur et forme :SolidMasse moléculaire :363.819-Isopropylolomoucine
CAS :<p>9-Isopropylolomoucine (N9-Isopropylolomoucine), a cell cycle protein-dependent kinase inhibitor, is a thiopurine.</p>Formule :C17H22N6ODegré de pureté :99.82%Couleur et forme :SolidMasse moléculaire :326.4CDK8-IN-1
CAS :<p>CDK8-IN-1 is a selective CDK8 inhibitor (IC50: 3 nM).</p>Formule :C11H8F3N3ODegré de pureté :98.48%Couleur et forme :SolidMasse moléculaire :255.2Cdc7-IN-7c
CAS :<p>Cdc7-IN-7c (Cdc7 inhibitor-7c) has antitumor activity and has inhibitory effect on liver cancer, lung cancer, kidney cancer, brain cancer and cervical cancer.</p>Formule :C15H17N5OSDegré de pureté :98.19% - 99.22%Couleur et forme :SolidMasse moléculaire :315.39SEL120-34A
CAS :<p>SEL120-34A inhibits CDK8 (IC50: 4.4 nM) & CDK19 (10.4 nM), less on CDK9 (1070 nM), has antitumor properties.</p>Formule :C15H18Br2N4Degré de pureté :99.764% - 99.84%Couleur et forme :SolidMasse moléculaire :414.14CDK4/6/1 Inhibitor
CAS :<p>CDK4/6/1 Inhibitor (Crozbaciclib) is a type of CDK4/6 inhibitor (IC50s: 3 and 1 nM).</p>Formule :C28H30F2N6Degré de pureté :99.26% - 99.72%Couleur et forme :SolidMasse moléculaire :488.57BML-259
CAS :<p>BML-259 inhibits CDK5/CDK2 (IC50: 64/98 nM) for cancer and neurodegeneration research.</p>Formule :C14H16N2OSDegré de pureté :99.84%Couleur et forme :SolidMasse moléculaire :260.35dCeMM2
CAS :<p>dCeMM2 degrades glue by promoting CDK12-cyclin K ubiquitination and degradation via CRL4B ligase interaction.</p>Formule :C16H11ClN6OSDegré de pureté :99.68%Couleur et forme :SolidMasse moléculaire :370.82Cdk2 Inhibitor II
CAS :<p>Cdk2 Inhibitor II is a selective and potent CDK2 inhibitor50 at 60 nM.</p>Formule :C14H11BrN4O3SDegré de pureté :97.07%Couleur et forme :SolidMasse moléculaire :395.23Abemaciclib metabolite M20
CAS :<p>Abemaciclib metabolite M20 (CDK4/6-IN-4) 是 Abemaciclib 的活性代谢物。 Abemaciclib metabolite M20 是一种特异性 CDK4/6 抑制剂，可用于癌症治疗的相关研究。</p>Formule :C27H32F2N8ODegré de pureté :98.1% - 99.08%Couleur et forme :SolidMasse moléculaire :522.59SHP2/CDK4-IN-1
CAS :<p>SHP2/CDK4-IN-1: dual inhibitor, oral, potent (IC50: SHP2 4.3 nM, CDK4 18.2 nM), hinders TNBC growth, strong antitumor effects in mice.</p>Formule :C33H35ClF2N10OSCouleur et forme :SolidMasse moléculaire :693.21CDK-IN-11
CAS :<p>CDK-IN-11, a heterocyclic compound, promotes cardiomyocyte maturation [1].</p>Formule :C25H21BrN4O2Couleur et forme :SolidMasse moléculaire :489.36CDK/HDAC-IN-3
CAS :<p>CDK/HDAC-IN-3 is an orally active dual inhibitor of HDACs and CDKs, offering potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2, and HDAC3,</p>Formule :C24H18Cl2N6O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :509.34Cdk4 Inhibitor
CAS :<p>PD 0332991, an unsymmetrical indolocarbazole compound, is cell-permeable and exhibits antiproliferative effects by functioning as a potent, selective, reversible, and ATP-competitive inhibitor of Cdk4/D1 (IC 50 = 76 nM). Although it can inhibit other Cdks, such as Cdk2/E and Cdk1/B, effectiveness requires higher concentrations (IC 50 = 520 nM and 2.1 µM, respectively) and demonstrates minimal activity against CaMKII, PKA, or GSK-3β (IC 50 ≥ 12.4 µM). PD 0332991 efficiently inhibits tumor cell growth in HCT-116 and NCI-H460 cell lines with an IC 50 < 3.0 µM, primarily through blocking Rb phosphorylation and inducing G1 cell cycle arrest.</p>Formule :C20H10BrN3O2Couleur et forme :SolidMasse moléculaire :404.2EHT 5372
CAS :<p>EHT 5372 inhibits DYRK kinases; IC50: 0.22-221 nM for DYRK1A/B, DYRK2/3, CLK1/2/4, GSK-3α/β.</p>Formule :C17H11Cl2N5OSCouleur et forme :SolidMasse moléculaire :404.27Nε-(1-Carboxyethyl)-L-lysine
CAS :<p>Nε-(1-Carboxyethyl)-L-lysine (CEL) is an advanced glycation end-product (AGE). Exposure to CEL reduces glutamate uptake and S100B secretion in the hippocampus.</p>Formule :C9H18N2O4Couleur et forme :SolidMasse moléculaire :218.25Lerociclib
CAS :<p>Lerociclib (G1T38) is a CDK4/6 inhibitor with anticancer and antitumor activities, inhibiting CDK4/CyclinD1 and CDK6/CyclinD3.</p>Formule :C26H34N8ODegré de pureté :99%Couleur et forme :SolidMasse moléculaire :474.6CDK8-IN-3
CAS :<p>CDK8-IN-3 is an inhibitor of CDK8.</p>Formule :C22H23N5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :389.45CDK9-IN-29
CAS :<p>CDK9-IN-29 (compound Z11) is a potent inhibitor of CDK9, exhibiting high kinase selectivity and an IC50 value of 3.20 nM.</p>Formule :C29H33F2N5O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :553.6IIIM-290
CAS :<p>IIIM-290 is an oral CDK inhibitor (IC50s: 90 and 94 nM for CDK2/A and CDK9/T1).</p>Formule :C23H21Cl2NO5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :462.32CCT-251921
CAS :<p>CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor (IC50: 2.3 nM).</p>Formule :C21H23ClN6ODegré de pureté :99.07%Couleur et forme :SolidMasse moléculaire :410.9CDK9-IN-8
CAS :<p>CDK9-IN-8 is a highly potent and selective CDK9 inhibitor (IC50: 12 nM).</p>Formule :C31H32FN7O3Degré de pureté :99.54%Couleur et forme :SolidMasse moléculaire :569.63QR-6401
CAS :<p>QR-6401, a selective macrocyclic CDK2 inhibitor, is orally active with IC50 values of 0.37 nM for CDK2/E1, 10 nM for CDK9/T1, 22 nM for CDK1/A2, 34 nM for CDK6/</p>Formule :C19H23N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :369.42Tacaciclib
CAS :<p>Tacaciclib is a cyclin-dependent kinase (CDK) inhibitor with observed antineoplastic activity [1].</p>Formule :C30H36N6O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :528.65Mevociclib
CAS :<p>Mevociclib (SY-1365) is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.</p>Formule :C31H35ClN8O2Degré de pureté :98.02% - 98.02%Couleur et forme :SolidMasse moléculaire :587.11Palbociclib orotate
CAS :<p>Palbociclib (PD 0332991) orotate, an orally active selective inhibitor of CDK4 and CDK6, exhibits IC50 values of 11 and 16 nM, respectively.</p>Formule :C29H33N9O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :603.63KM05382
CAS :<p>KM05382 inhibits CDK9 and the transcription of GAPDH.</p>Formule :C20H19ClN2O3S2Couleur et forme :SolidMasse moléculaire :434.96CDK4-IN-2
CAS :<p>CDK4-IN-2 (A17) is a potent inhibitor of CDK4, exhibiting K i and IC 50 values of less than 10 nM and is utilized in cancer research [1].</p>Formule :C22H26F2N6O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :508.54DCB-3503
CAS :<p>DCB-3503, a tylophorine analog, may fight cancer and aid immunosuppression by hindering protein synthesis and modulating HSC70 ATPase function.</p>Formule :C24H27NO5Couleur et forme :SolidMasse moléculaire :409.47LDC3140
CAS :<p>LDC3140 is a potent inhibitor of Cyclin-dependent kinase 7 (CDK7).</p>Formule :C23H33N7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :423.55Leucettinib-92
CAS :<p>Leucettinib-92 (compound 92) is a kinase inhibitor selective for DYRK/CLK families, displaying IC50 values of 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM</p>Formule :C21H22N4OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :378.49CDK9-IN-9
CAS :<p>CDK9-IN-9 is a potent and selective CDK9 inhibitor (IC50: 1.8 nM) with anti-cancer activity. It inhibits CDK2 (IC50: 155 nM).</p>Formule :C22H23F2N5O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :459.51(2S,3R)-Voruciclib
CAS :<p>(2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. It is an orally active CDK inhibitor.</p>Formule :C22H19ClF3NO5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :469.84CDK9-IN-2
CAS :<p>CDK9-IN-2, a CDK9 inhibitor from patent WO/2012131594A1, IC50: 5 nM in A2058, 7 nM in H929 at 72hr.</p>Formule :C23H25ClFN5Degré de pureté :99%Couleur et forme :SolidMasse moléculaire :425.93CDK7-IN-14
CAS :<p>CDK7-IN-14, a potent CDK7 inhibitor from pyrimidines, may treat transcriptionally dysregulated cancers (CN114249712A).</p>Formule :C22H24F3N6OPCouleur et forme :SolidMasse moléculaire :476.435-Iodo-indirubin-3'-monoxime
CAS :<p>5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase (IC50s</p>Formule :C16H10IN3O2Couleur et forme :SolidMasse moléculaire :403.17NU6300
CAS :<p>NU6300 is a covalent CDK2 inhibitor exhibiting irreversible and ATP-competitive properties and also functions as a GSDMD (Gasdermin D) inhibitor.</p>Formule :C20H23N5O3SDegré de pureté :96.08%Couleur et forme :SolidMasse moléculaire :413.49Voruciclib hydrochloride
CAS :<p>Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM).</p>Formule :C22H20Cl2F3NO5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :506.3PF-6808472
CAS :<p>PF-6808472 is a cell-permeable covalent kinase probe, reacts with conserved lysine residues within the ATP-binding site of kinases.</p>Formule :C25H27FN8O3SDegré de pureté :99.02%Couleur et forme :SolidMasse moléculaire :538.6CDK7-IN-22
CAS :<p>CDK7-IN-22 (compound 101) is a selective CDK7 inhibitor that exhibits antitumor activity, demonstrating specificity for CDK7 [1].</p>Formule :C22H25F3N6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :430.47
